Daxor Announces Publication in the Journal of Nuclear Medicine Technology on Expanding Clinical Applications and Use of Blood Volume Analysis
NEW YORK, NY--(Marketwire - May 29, 2007) - Daxor Corporation (AMEX: DXR), a medical
instrumentation and biotechnology company, today announced the June 2007
publication of the Journal of Nuclear Medicine Technology article, "Blood
Volume Analysis: A New Technique and New Clinical Interest Reinvigorate a
Classic Study." The article was authored by Dr. Timothy Manzone, Department
of Nuclear Medicine, Christiana Care Health System and others, and features
the fundamental concepts of a blood volume measurement and how Daxor's
Blood Volume Analyzer BVA-100 and related clinical studies have
demonstrated improved clinical management in heart failure, critical care
and various other medical conditions. The Journal of Nuclear Medicine
Technology (JNMT) along with the Journal of Nuclear Medicine (JNM) are the
most widely read peer-reviewed publications in nuclear medicine and allied
disciplines. Practitioners from across the imaging sciences turn to JNMT
for peer-reviewed information related to daily clinical practice.
The article reviewed the technical history of blood volume measurement and
focused on the difficulty of performing an accurate and timely blood volume
measurement until the introduction of Daxor's BVA-100 system. The authors
conclude that "...blood volume analysis reports of today include
extraordinarily fundamental clinical parameters we could not previously
measure." In addition, they state that facilities which commit to
providing an automated blood volume analysis "will be rewarded and will
contribute significantly to patient care." Daxor Corporation manufactures
and markets the only FDA-approved semi-automated Blood Volume Analyzer
BVA-100 for the measurement of human blood volume. The Daxor BVA-100 is
used in conjunction with Volumex, Daxor's single use diagnostic kit.
One of the studies cited within the article discusses how clinical
assessment of the volume status of heart failure patients without a blood
volume analysis is only correct 51% of the time, and how patients who
remain volume overloaded have a 2-year mortality rate of 55% versus a 0%
mortality rate of patients who are treated to a normal blood volume. The
authors also note the application of blood volume measurement in the
management of medical conditions in hematology, cardiology, surgery and
critical care medicine.
The article qualifies for medical continuing education (CE) credits for
Nuclear Medicine professionals, which are received after reading the
article and applying for the CE credits online through the Society of
Nuclear Medicine.
For more information regarding Daxor Corporation's Blood Volume Analyzer
BVA-100, visit Daxor's website www.Daxor.com.